Lilly Gets Ready To Compete With Its Late-Stage Diabetes Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Indianapolis-based pharma highlighted the Phase III results from two of its most promising pipeline candidates at ADA. The company is preparing to have four new diabetes drugs on the market by 2016, including two basal insulins, a GLP-1 agonist and a SGLT-2 inhibitor.